Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging

Trial Profile

Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 16 Jun 2018 Results assessing Tc 99M Tilmanocept Localization in Active Rheumatoid Arthritis (Ra) Subjects by Planar and Spect/Ct, presented at the 19th Annual Congress of the European League Against Rheumatism
    • 14 Dec 2016 Status changed from recruiting to completed.
    • 03 Nov 2016 According to a Navidea Biopharmaceuticals media release, to date, 17 of 18 patients have been dosed and imaged in the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top